In this section
@article{Kis:2022:10.1038/s41541-022-00447-3,
author = {Kis, Z and Tak, K and Ibrahim, D and Papathanasiou, M and Chachuat, B and Shah, N and Kontoravdi, C},
doi = {10.1038/s41541-022-00447-3},
journal = {npj Vaccines},
title = {Pandemic-response adenoviral vector and RNA vaccine manufacturing},
url = {http://dx.doi.org/10.1038/s41541-022-00447-3},
volume = {7},
year = {2022}
}
TY - JOUR
AB - Rapid global COVID-19 pandemic response by mass vaccination is currently limited by the rate of vaccine manufacturing. This study presents a techno-economic feasibility assessment and comparison of three vaccine production platform technologies deployed during the COVID-19 pandemic: (1) adenovirus-vectored (AVV) vaccines, (2) messenger RNA (mRNA) vaccines, and (3) the newer self-amplifying RNA (saRNA) vaccines. Besides assessing the baseline performance of the production process, impact of key design and operational uncertainties on the productivity and cost performance of these vaccine platforms is evaluated using variance-based global sensitivity analysis. Cost and resource requirement projections are computed for manufacturing multi-billion vaccine doses for covering the current global demand shortage and for providing annual booster immunisations. The model-based assessment provides key insights to policymakers and vaccine manufacturers for risk analysis, asset utilisation, directions for future technology improvements and future pidemic/pandemic preparedness, given the disease-agnostic nature of these vaccine production platforms.
AU - Kis,Z
AU - Tak,K
AU - Ibrahim,D
AU - Papathanasiou,M
AU - Chachuat,B
AU - Shah,N
AU - Kontoravdi,C
DO - 10.1038/s41541-022-00447-3
PY - 2022///
SN - 2059-0105
TI - Pandemic-response adenoviral vector and RNA vaccine manufacturing
T2 - npj Vaccines
UR - http://dx.doi.org/10.1038/s41541-022-00447-3
UR - https://www.nature.com/articles/s41541-022-00447-3
VL - 7
ER -